Lesley Seymour

发表

13 From warehouse to new RECIST criteria

Jan Bogaerts, Saskia Litière, Lesley Seymour, 2012 .

Data warehouse and uncertainties in response measurements

Jan Bogaerts, Lesley Seymour, de Elisabeth G. E. Vries, 2013 .

Phase I Studies of New Therapeutics An Overview of the Optimal Planning, Design, and Conduct of

Lesley Seymour, Patricia LoRusso, Scott A. Boerner, 2010 .

Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

Igor Jurisica, Kerby Shedden, Steven Eschrich, 2008, Nature Medicine.

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Robert Livingston, Lesley Seymour, Ming-Sound Tsao, 2005, The New England journal of medicine.

Association of the 15q25 and 5p15 Lung Cancer Susceptibility Regions with Gene Expression in Lung Tumor Tissue

Lesley Seymour, Melania Pintilie, Ming-Sound Tsao, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

Gwénaël Le Teuff, Lesley Seymour, Ming-Sound Tsao, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

Susan Groshen, Larry Rubinstein, Lesley Seymour, 2010, Clinical Cancer Research.

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

Brian Findlay, Lesley Seymour, Ming-Sound Tsao, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Lesley Seymour, Ming-Sound Tsao, Suzanne Kamel-Reid, 2005, The New England journal of medicine.

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.

Lesley Seymour, L. Seymour, F. Shepherd, 2003, The Lancet. Oncology.

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Percy Ivy, Xavier Paoletti, Laurence Collette, 2014, European journal of cancer.

Tumor Shrinkage and Objective Response Rates: Gold Standard for Oncology Efficacy Screening Trials, or an Outdated End Point?

Lesley Seymour, L. Seymour, P. Bradbury, 2009, Cancer journal.

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

Eric Sauerbrei, Stephen Chia, Karen A Gelmon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Richard J Stephens, Lesley Seymour, Valter Torri, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval

Dongsheng Tu, Lesley Seymour, L. Seymour, 2005, Clinical Cancer Research.

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Robert Ford, Otto S Hoekstra, Yan Liu, 2016, European journal of cancer.

An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics

Lesley Seymour, L. Seymour, P. LoRusso, 2010, Clinical Cancer Research.

Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.

Igor Jurisica, Matthew Meyerson, Lesley Seymour, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Robert Ford, Otto S Hoekstra, Lawrence H Schwartz, 2017, The Lancet. Oncology.

RECIST — learning from the past to build the future

Lesley Seymour, Saskia Litière, Elisabeth G. E. de Vries, 2017, Nature Reviews Clinical Oncology.

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.

Gwénaël Le Teuff, Elisabeth Brambilla, Lesley Seymour, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics.

Lesley Seymour, 2003, Current opinion in investigational drugs.

Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.

Lesley Seymour, G. Scagliotti, J. Pignon, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib in previously treated non-small-cell lung cancer.

Renato Martins, Andrea Bezjak, Dongsheng Tu, 2005, The New England journal of medicine.

Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.

Lesley Seymour, L. Seymour, K. Ding, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternate Endpoints for Screening Phase II Studies

Daniel J Sargent, Dongsheng Tu, Lesley Seymour, 2009, Clinical Cancer Research.

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Lesley Seymour, Ming-Sound Tsao, Suzanne Kamel-Reid, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.